Loading...

PR Information Data

Seminar from AdipoLABs on 'Necessity of Hyperthermia Cancer Treatment and Case Report' was Successfully Completed : 2018.03.18
18-03-18 09:23 3,357회 0건

People are taking a commemorative photo after the seminar of 'Necessity and Case Report of Hyperthermia Immune Cancer Treatment'. (Photo: Reporter Min Kyung-chan)


(Seoul = International News) Reporter Min Kyung-chan = On the past 15th of March, AdipoLABs presented a seminar of 'Necessity and Case Report of Hyperthermia Immune Cancer Treatment' at 2018 KIMES.

AdipoLABs (CEO Han Sung-ho) presented to 200 participants who showed interest in treating cancer through heat and immunization on the 2nd day of the opening day at KIMES. Former director Son Moon-ki from the Ministry of Food and Drug Safety, Chung Seung-won, director of the CP Group of Thailand, Chairman, Yoon Seok-hun from Chamber of Commerce of Korea and Iran all attended the seminar.

The seminar began with the lecture on 'Principles of Hyperthermia' by Kang Young-nam who is a Professor of Radiation Oncology at Catholic University College of Medicine, Korea followed by 'Cancer and Hyperthermia' by Hong-Seok Jang, Professor of Radiation Oncology, Catholic University Medical College, 'Hyperthermia and immunotherapy' by Il-bong Choi, Chairman of the Korean Society of Thermal Medicine and Asian Congress of Hyperthermic Oncology, 'Korean Cancer Treatment and Thermotherapy' by Jong-chun Joo, Korean medicine professor at Won-kwang University and "The Effect and the Positive Results of High-frequency Hyperthermia Cancer Treatment by Park Soo-jeong, professor of Constitutional Medicine at Woosuk University.

This seminar received positive feedbacks since it had introduced a new, fourth method of cancer treatment to various hospitals, medical personnel, and cancer patients and their families who have been looking for an innovative treatment besides surgery, chemotherapy and radiation therapy on cancer.

Professor Choi Il-bong, chairman of the Korean Society of Thermal Medicine, led the repercussions of cancer patients who improved after the procedure with AdipoLABs' 'REMISSION 1°C'.

REMISSION 1°C is shown in SCIE level-paper for improvement of patients with cholangiocarcinoma, improvement of lymph node metastases breast cancer patients, improvement of patients with severe lymph node edema after breast cancer treatment, stage 3 patients with inoperable pancreatic cancer. Many cases are shown, including some of the patients who have experienced a complete cure.

In particular, the improvement of pancreatic cancer, which is classified as malignant cancer, is rare, and therefore, its clinical significance is greater.

Prof. Choi Il-bong said "Hyperthermia treatment with REMISSION 1°C increases the activity of natural killer cells (NK Cells) to enhance the immune system of cancer patients." "It is better to combine with standard cancer treatment because REMISSION 1°C improves the immunodeficiency that occurs during radiation therapy."

"REMISSION 1°C enhances the body's immune function, helping to prevent cancer from recurring or spreading. The device reduces tumor growth therefore increasing the patient's survival rate."

AdipoLABs' Han Sung-ho said, “To meet the expectations of medical and cancer patients at the exhibition and seminar, we will try harder to give miracle to these suffering cancer patients and their families in near future."

The seminar was sponsored by the Korean Society of Thermal Medicine, the Catholic Institute of Advanced Convergence Radiation Medical Technology, Biosin Korea, International News, and News In Media.